Event: | |
Presentation: | On-demand virtual presentation |
Date: | |
Link: | https://investors.in8bio.com/news-events/events-presentations |
Event: | Solebury Trout Virtual 2022 1x1 Management Access Event |
Presentation: | 1x1’s |
Date: | |
Link: | https://bit.ly/trout2022 |
Event: | Biotech Showcase 2022 |
Presentation: | Panel Discussion: Outsmarting Cancer: Next Generation Therapies |
Date: | |
Link: | https://bit.ly/3F5ZKXH |
Presentation: | On-demand virtual presentation |
Date: | |
Link: | https://partneringone.informaconnect.com/event/716/company/358 |
Event: | B. |
Presentation: | Fireside Chat and 1x1’s |
Date: | |
Link: | https://www.webcaster4.com/Webcast/Page/2828/44085 |
About
The proprietary IN8bio DeltEx platform is designed to overcome many of the challenges associated with the expansion, genetic engineering, and scalable manufacturing of gamma-delta T cells. The DeltEx platform employs allogeneic, autologous, and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells. This approach allows us to expand the cells ex vivo to administer a potentially therapeutic dose to patients, harnessing the unique properties of gamma-delta T cells, including their ability to broadly recognize cellular stress signals on tumor cells. We have used the DeltEx platform to create our deep pipeline of innovative allogeneic, autologous and/or genetically modified product candidates designed to effectively target and potentially eradicate disease and improve patient outcomes.
For more information about
Company Contact:
+1 646.600.6GDT (6438)
cbutler@IN8bio.com
Investors:
Solebury Trout
+ 1 646.378.2927
dbuck@soleburytrout.com
Media:
rflamm@burnsmc.com / klarch@burnsmc.com
![](https://ml.globenewswire.com/media/NTljYWUwMGUtNTBhZS00YzdiLWE3MGMtNThlYjkxYWUwZDJkLTExMzQ1Nzc=/tiny/IN8bio-Inc.png)
2022 GlobeNewswire, Inc., source